Sweden · Delayed Price · Currency is SEK Vivesto AB Earnings Call Transcripts
Fiscal Year 2026
-
Dog and cat top-line studies confirmed safety and tolerability, with no hypersensitivity; canine data showed doubled overall survival versus surgery alone. Next steps include pivotal-study planning, regulatory discussions, manufacturing work and partner outreach.
Fiscal Year 2025
-
Recent interim results show Pakalvet doubles median survival in dogs with hemangiosarcoma, while Cantrixil demonstrates strong efficacy in preclinical hematological cancer models. Key studies are set to complete next year, with active partnering efforts underway to accelerate market entry.
-
The update highlights a focused oncology strategy with strong interim results for Paccal Vet in dogs and promising early data in cats, as well as preclinical success for Cantrixil in AML. A SEK 53.8M rights issue will fund key studies and partnering efforts, targeting major milestones in 2026.